Stockscreener 앱 받기
32.91
1.38%
-0.46
전일 마감가:
$33.37
열려 있는:
$33.99
하루 거래량:
972.70K
Relative Volume:
2.63
시가총액:
$608.90M
수익:
$299.77M
순이익/손실:
$364.23M
주가수익비율:
1.7579
EPS:
18.7211
순현금흐름:
$79.27M
1주 성능:
+2.59%
1개월 성능:
+15.03%
6개월 성능:
-21.21%
1년 성능:
+69.99%
1일 변동 폭
$32.42
$34.15
1주일 범위
$31.80
$34.39
52주 변동 폭
$18.14
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
32.91 | 608.90M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Liquidity Mapping Around (RIGL) Price Events - Stock Traders Daily
Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rigel Pharmaceuticals secures rights to develop and market VEPPANU under new agreement - Traders Union
Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Institutional Confidence - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rigel Pharmaceuticals (RIGL) Secures Global Rights for Breast Ca - GuruFocus
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal - MSN
Rigel closes license deal for breast cancer drug VEPPANU, plans commercial launch in August - Pluang
Pfizer trades up with Rigel’s Veppanu deal done - TechStock²
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv - Bitget
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) - PR Newswire
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rigel Pharmaceuticals (RIGL) Advances 2.13%: Testing Resistance at $32.26Leveraged ETF Flow - newsline.com
RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart - ChartMill
Why (RIGL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Rigel Pharmaceuticals Edges Higher: Testing Key Resistance at $31.61Gap Up Stocks - newsline.com
Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals - Benzinga
Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes - Stock Titan
Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations - Stock Titan
Rigel (RIGL) CMO uses 850 shares to cover stock tax liability - Stock Titan
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations - Stock Titan
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
Rigel Pharmaceuticals Gains Momentum, Testing Key Resistance at $32.14Straddle Setup - newsline.com
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar - GuruFocus
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Pharmaceuticals Inc (RIGL) - GuruFocus
Understanding Momentum Shifts in (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade - Stock Titan
Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines - Yahoo Finance
Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference - GuruFocus
Rigel Pharmaceuticals to Present at Jefferies Global Healthcare Conference on May 27, 2026 - geneonline.com
Rigel (RIGL) Gains Momentum as Kissei Submits NDA for Rezlidhia in Japan - GuruFocus
Rigel Pharmaceuticals (RIGL) Gains Nearly 2% as Stock Tests Key Resistance Near $31.24High Reward Trades - thelegaladvocate.com
Rigel Pharmaceuticals Acquires Global Rights to Veppanu in $85 Million Deal, Targeting ESR1-Mutated Breast Cancer - geneonline.com
Biotech CEO to give Rigel company overview at Jefferies healthcare conference - Stock Titan
Rigel to Present at the Jefferies Global Healthcare Conference – Company Announcement - Financial Times
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
RIGL Technical Analysis | Trend, Signals & Chart Patterns | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress - PR Newswire
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):